Biologics for the prophylaxis and treatment of COVID-19

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA85475

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $1,511,057.58
  • Funder

    National Health and Medical Research Council (NHMRC)
  • Principal Investigator

    N/A

  • Research Location

    Australia
  • Lead Research Institution

    Walter and Eliza Hall Institute of Medical Research
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Agents for treatments and prevention of COVID-19 infection are urgently needed. Antibodies are widely used to treat several infectious diseases, as well as autoimmune diseases and cancer. Using novel antibody discovery platforms and high-throughput screening approaches, our team of academic and industry partners is uniquely positioned to accelerate the discovery of an effective and safe antibody-based therapy to combat the new pandemic coronavirus.